Amicus Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics to Present at 31st Annual J.P. Morgan Healthcare
Conference

CRANBURY, N.J., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing
therapies for rare and orphan diseases, today announced that John F. Crowley,
Chairman and Chief Executive Officer, will present a corporate overview at the
31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on
Wednesday, January 9, 2013 at 3:00 p.m. PT.

A live webcast of the presentation can be accessed through the Investors
section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
Participants are encouraged to visit the web site 10 minutes prior to the
start of the presentation to register, download and install any necessary
software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of developing therapies for rare and orphan diseases. The Company is
developing orally-administered, small molecule drugs called pharmacological
chaperones, a novel, first-in-class approach to treating a broad range of
human genetic diseases. Amicus' late-stage programs for lysosomal storage
disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease;
migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase
2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe
disease.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044